European Companies Search Engine
EU funding (€5,331,000): Neurotoxicity De-Risking in Preclinical Drug Discovery Hor1 Mar 2019 EU Research and Innovation programme "Horizon"
Overview
Text
Neurotoxicity De-Risking in Preclinical Drug Discovery
The adverse effects of pharmaceuticals on the central or peripheral nervous systems are poorly predicted by the current in vitro and in vivo preclinical studies performed during Research and Development (R&D) process. Therefore, increasing the predictivity of the preclinical toolbox is a clear need, and would benefit to human volunteers/patients (safer drugs) and Pharmaceutical Industry (reduced attrition). By combining top level scientists in neurobiology/toxicology with successful software developers, the NeuroDeRisk | Neurotoxicity De-Risking in Preclinical Drug Discovery Consortium will aim at tackling three of the most challenging adverse effects: seizures, psychological/psychiatric changes, and peripheral neuropathies. Our approach will be global, starting with an in-depth evaluation of knowledge on mechanisms of neurotoxicity (biological pathways as well as chemical structures and descriptors, using in particular historical data). Then we will search for innovative tools, assays and studies covering in silico, in vitro and in vivo approaches. This will include in particular: molecular design platform, artificial intelligence, human induced pluripotent stem cells, blood-brain-barrier models, immunohistochemistry, transcriptomics, RNA editing biomarkers, video-monitoring and telemetry of animals, pharmacokinetics, etc. The last step will aim at combining these tools in an integrated platform for better risk-assessment and decision-points throughout R&D process, and thus better protection of human volunteers and patients.
Funded Companies:
| Company name | Funding amount |
| A. Persidis & SIA ΟΕ | €406,800 |
| Alcediag | €583,300 |
| Astrazeneca AB | €0.00 |
| Farmaceutski Fakultet Univerziteta U Beogradu | €696,150 |
| FUJIFILM CELLULAR DYNAMICS Inc. | €0.00 |
| Iceta Instituto de Ciencias, Tecnologias e Agroambiente da Universidade do Porto | €403,500 |
| Inte:Ligand Software-Entwicklungs-UND Consulting GmbH | €341,400 |
| ITA-SUOMEN YLIOPISTO | €804,900 |
| Medizinische Universitaet Wien | €372,200 |
| MERCK SHARP & DOHME Corp. | €0.00 |
| NOVARTIS PHARMA AG | €0.00 |
| Pfizer Ltd. | €0.00 |
| Sanofi-Aventis Recherche & Developpement | €0.00 |
| UCB Biopharma | €0.00 |
| Universita Degli Studi Di Firenze | €391,500 |
| Universitat Wien | €594,450 |
| Universite Clermont Auvergne | €429,400 |
| Uppsala Universitet | €307,400 |
Source: https://cordis.europa.eu/project/id/821528
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "A. Persidis & SIA OE - EU funding (€5,331,000): Neurotoxicity De-Risking in Preclinical Drug Discovery"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
